文献速递类风湿关节炎系统性红斑狼疮血管炎

英国风湿与肌肉骨骼疾病患者利妥昔单抗治疗期间SARS-CoV-2突破性感染及中重度结局预测:单中心队列研究

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
PubMed 文献 · Lancet Rheumatol · 2023-01-10

该单中心回顾性队列纳入400例接受利妥昔单抗治疗的风湿与肌肉骨骼疾病患者,评估SARS-CoV-2突破性感染发生率及中重度COVID-19预测因素。完全接种者中30%发生突破性感染,4%为中重度,仅1例死亡;完全接种者中重度COVID-19发生率低于未完全接种者。合并症数量及低丙种球蛋白血症与中重度COVID-19风险升高相关,每增加一剂疫苗可降低风险。

要点

  • 完全接种的利妥昔单抗治疗患者中,30%发生突破性感染,4%为中重度COVID-19,1例死亡。
  • 完全接种者中重度COVID-19发生率为3.32/100人年,低于未完全接种者的25.56/100人年。
  • 合并症数量(HR 1.46)和低丙种球蛋白血症(HR 3.22)与中重度COVID-19风险升高相关。

核心结论

  • 在大流行后期,完全接种疫苗的利妥昔单抗治疗患者SARS-CoV-2突破性感染率较高,但中重度COVID-19发生率与任何严重感染事件发生率相近。
  • 对于其他治疗选择有限的重度风湿与肌肉骨骼疾病患者,接种疫苗后利妥昔单抗的风险-获益比可能仍有利。
  • 存在合并症和低丙种球蛋白血症时,需对所有感染类型保持警惕。

研究设计与样本

  • 英国利兹单中心回顾性队列研究,纳入2020年3月1日至2022年4月1日期间所有接受利妥昔单抗治疗的风湿与肌肉骨骼疾病患者。
  • 纳入标准为年龄≥18岁、符合既定风湿与肌肉骨骼疾病分类标准、且在2019年9月1日至2022年4月1日期间接受至少一次利妥昔单抗输注。
  • 最终分析纳入400例患者,平均年龄58.9岁(SD 14.6),女性288例(72%),男性112例(28%),白人333例(83%),110例(28%)有两种或以上合并症。
  • 疾病分布:类风湿关节炎272例(68%),系统性红斑狼疮48例(12%),抗中性粒细胞胞质抗体相关血管炎48例(12%),其他风湿与肌肉骨骼疾病46例(12%)。
  • 突破性感染定义为第二剂疫苗后≥14天发生的感染;中重度COVID-19定义为需氧支持的住院或死亡。

主要发现

  • 研究期间共给予798个利妥昔单抗周期;400例患者中398例(>99%)有疫苗数据,其中372例(93%)完全接种。
  • 随访774.6人年期间,SARS-CoV-2各严重类型感染在三个大流行阶段(野生型或alpha、delta、omicron)呈递增趋势,但大多数感染为轻度;中重度COVID-19发生率在三个变异阶段大致相似。
  • 370例完全接种且数据完整的患者中,110例(30%)发生所有严重类型的突破性感染,16例(4%)发生中重度突破性感染,1例(<1%)死亡。
  • 接种后阶段(2020年12月18日后),完全接种者所有严重类型感染发生率为22.83/100人年(95%CI 18.94-27.52),低于部分接种或未接种者的89.46/100人年(95%CI 52.98-151.05);中重度感染发生率为3.32/100人年(95%CI 2.03-5.42),低于部分接种或未接种者的25.56/100人年(95%CI 9.59-68.10)。
  • 该队列中中重度COVID-19发生率与其他严重感染事件发生率大致相似(5.68/100人年,95%CI 4.22-7.63)。

关键数值与推荐

  • 多变量Cox回归显示,合并症数量与中重度COVID-19风险升高相关(HR 1.46,95%CI 1.13-1.89;p=0.0037)。
  • 低丙种球蛋白血症(利妥昔单抗前IgG浓度<6 g/L)与中重度COVID-19风险升高相关(HR 3.22,95%CI 1.27-8.19;p=0.014)。
  • 每接受一剂疫苗,中重度COVID-19风险降低(HR 0.49,95%CI 0.37-0.65;p<0.0001)。
  • 同时使用泼尼松龙、利妥昔单抗相关因素(如利妥昔单抗剂量及末次利妥昔单抗至接种时间)和疫苗相关因素(如疫苗类型及外周B细胞耗竭)未显示可预测中重度COVID-19结局。

临床怎么用

  • 对于其他治疗选择有限的重度风湿与肌肉骨骼疾病患者,接种疫苗后利妥昔单抗的风险-获益比可能仍有利。
  • 存在合并症和低丙种球蛋白血症时,需对所有感染类型保持警惕。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskeletal diseases are largely unknown. We aimed to assess the incidence of breakthrough SARS-CoV-2 infection, compare rates of moderate-to-severe COVID-19 with any severe infection event, and evaluate predictors of moderate-to-severe COVID-19 outcomes in patients treated with rituximab. METHODS: We did a retrospective cohort study in all rituximab-treated patients with rheumatic and musculoskeletal diseases in a single centre in Leeds, UK between March 1, 2020 (the index date), and April 1, 2022. Adults aged 18 years and older, who fulfilled classification criteria for established rheumatic and musculoskeletal diseases, and received therapy with at least one rituximab infusion between Sept 1, 2019 (6 months before the pandemic in the UK), and April 1, 2022, were eligible for inclusion in the study. SARS-CoV-2 infection was defined by antigen test or PCR. COVID-19 outcomes were categorised as mild (from ambulatory to hospitalised but not requiring oxygen support) or moderate-to-severe (hospitalised and requiring oxygen support or death). The primary outcome was breakthrough COVID-19 infection, which was defined as an infection occurring 14 days or more after the second vaccine dose. Predictors of moderate-to-severe COVID-19 outcomes were analysed using Cox regression proportional hazards. FINDINGS: Of the 1280 patients who were treated with at least one cycle of rituximab since Jan 1, 2002, 485 (38%) remained on rituximab therapy on April 1, 2022. Of these patients, 400 fulfilled all inclusion criteria and were included in our final analysis. The mean age at the index date was 58·9 years (SD 14·6), 288 (72%) of 400 patients were female and 112 (28%) were male, 333 (83%) were White, and 110 (28%) had two or more comorbidities. 272 (68%) of 400 patients had rheumatoid arthritis, 48 (12%) had systemic lupus erythematosus, 48 (12%) had anti-neutrophil cytoplasmic antibody-associated vasculitis, and 46 (12%) had other rheumatic and musculoskeletal diseases. During the study, 798 rituximab cycles were administered. Of the 398 (>99%) of 400 patients with vaccine data, 372 (93%) were fully vaccinated. Over the 774·6 patient-years of follow-up, there was an incremental increase in all SARS-CoV-2 severity types over the three pandemic phases (wild-type or alpha, delta, and omicron), but most infections were mild. The rates of moderate-to-severe COVID-19 were broadly similar across these three variant phases. Of 370 patients who were fully vaccinated and with complete data, 110 (30%) had all severity type breakthrough COVID-19, 16 (4%) had moderate-to-severe breakthrough COVID-19, and one (<1%) died. In the post-vaccination phase (after Dec 18, 2020), the incidence rates of all severity type and moderate-to-severe COVID-19 were substantially lower in those who were fully vaccinated compared with unvaccinated or partially vaccinated individuals (22·83 per 100 person-years [95% CI 18·94-27·52] in those who were fully vaccinated vs 89·46 per 100 person-years [52·98-151·05] in those who were partially vaccinated or unvaccinated for infections of all severities, and 3·32 per 100 person-years [2·03-5·42] in those who were fully vaccinated vs 25·56 per 100 person-years [9·59-68·10] in those who were partially vaccinated or unvaccinated for moderate-to-severe infections). The rate of moderate-to-severe COVID-19 was broadly similar to other severe infection events in this cohort (5·68 per 100 person-years [95% CI 4·22-7·63]). In multivariable Cox regression analysis, factors associated with an increased risk of moderate-to-severe COVID-19 were the number of comorbidities (hazard ratio 1·46 [95% CI 1·13-1·89]; p=0·0037) and hypogammaglobulinaemia (defined by a pre-rituximab IgG concentration of <6 g/L; 3·22 [1·27-8·19]; p=0·014). This risk was reduced with each vaccine dose received (0·49 [0·37-0·65]; p<0·0001). Other factors, including concomitant prednisolone use, rituximab-associated factors (eg, rituximab dose and time to vaccination since last rituximab dose), and vaccine-associated factors (eg, vaccine type and peripheral B-cell depletion) were not predictive of moderate-to-severe COVID-19 outcomes. INTERPRETATION: This study presented detailed analyses of rituximab-treated patients during various phases of the COVID-19 pandemic. In later stages of the pandemic, the SARS-CoV-2 breakthrough infection rate was high but severe COVID-19 rates were similar to any severe infection event rate in patients who were vaccinated. The risk-benefit ratio might still favour rituximab in vaccinated patients with severe rheumatic and musculoskeletal diseases who have few other treatment options. Increased vigilance is needed in the presence of comorbidities and hypogammaglobulinaemia for all infection types. FUNDING: Wellcome Trust and Eli Lilly.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Arnold J, Saleem B, et al. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Lancet Rheumatol. 2023. PMID: 36712951. doi:10.1016/S2665-9913(23)00004-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。